PCN45 Analysis of Societal Costs Due to Work Productivity Loss and Activity Impairment from the Monaleesa-7 Trial of Ribociclib + Endocrine Therapy (ET) in Premenopausal Women with HR+/HER2– Advanced Breast Cancer (ABC) in Brazil

2021 ◽  
Vol 24 ◽  
pp. S27
Author(s):  
T. Curteis ◽  
D. Chandiwana ◽  
P. Pathak ◽  
B. Lanoue ◽  
A. Buehler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Productivity Loss ◽  
Work Productivity ◽  
Premenopausal Women ◽  
Advanced Breast ◽  
Activity Impairment ◽  
Societal Costs

Results of first line endocrine therapy for advanced breast cancer in premenopausal women with skeletal metastases only

The Breast ◽  
1993 ◽  
Vol 2 (3) ◽  
pp. 203-204 ◽  
Author(s):  
W. Jonat ◽  
M. Kaufmann ◽  
R. Blamey ◽  
A. Howell ◽  
J. Collins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Premenopausal Women ◽  
Advanced Breast ◽  
Skeletal Metastases ◽  
First Line

scholarly journals Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA‐3 Results

2017 ◽  
Vol 22 (9) ◽  
pp. 1028-1038 ◽  
Author(s):  
Sibylle Loibl ◽  
Nicholas C. Turner ◽  
Jungsil Ro ◽  
Massimo Cristofanilli ◽  
Hiroji Iwata ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Premenopausal Women ◽  
Advanced Breast

scholarly journals Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Olga Martínez-Sáez ◽  
Tomás Pascual ◽  
Fara Brasó-Maristany ◽  
Nuria Chic ◽  
Blanca González-Farré ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Methodological Approach ◽  
Progression Free Survival ◽  
Circulating Tumor Dna ◽  
Advanced Breast ◽  
Dna Dynamics ◽  
Ca 15.3 ◽  
Tumor Dna

AbstractCirculating tumor DNA (ctDNA) levels may predict response to anticancer drugs, including CDK4/6 inhibitors and endocrine therapy combinations (CDK4/6i+ET); however, critical questions remain unanswered such as which assay or statistical method to use. Here, we obtained paired plasma samples at baseline and week 4 in 45 consecutive patients with advanced breast cancer treated with CDK4/6i+ET. ctDNA was detected in 96% of cases using the 74-gene Guardant360 assay. A variant allele fraction ratio (VAFR) was calculated for each of the 79 detected mutations between both timepoints. Mean of all VAFRs (mVAFR) was computed for each patient. In our dataset, mVAFR was significantly associated with progression-free survival (PFS). Baseline VAF, on-treatment VAF or absolute changes in VAF were not associated with PFS, nor were CA-15.3 levels at baseline, week 4 or the CA-15.3 ratio. These findings demonstrate that ctDNA dynamics using a standardized multi-gene panel and a unique methodological approach predicts treatment outcome. Clinical trials in patients with an unfavorable ctDNA response are needed.

Sign in / Sign up

Export Citation Format

Share Document